245 related articles for article (PubMed ID: 8073643)
1. [Tumor markers in the diagnosis of tumors in the subhepatic area].
Dufek V; Petrtýl J; Klener P; Chmel J
Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical analysis for cholangiocarcinoma].
Nakagoe T; Matsuo T; Kondoh M; Yamaguchi H
Nihon Rinsho; 2006 Jan; 64 Suppl 1():370-4. PubMed ID: 16457285
[No Abstract] [Full Text] [Related]
4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
5. Serum and bile markers for cholangiocarcinoma.
Nehls O; Gregor M; Klump B
Semin Liver Dis; 2004 May; 24(2):139-54. PubMed ID: 15192787
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
7. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
Harmenberg U; Wahren B; Wiechel KL
Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
10. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
11. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
14. Levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in sera and pancreatic juice in the diagnosis of pancreatic cancer.
Lin JT; Wang TH; Chen DS; Sung JL
Taiwan Yi Xue Hui Za Zhi; 1987 Aug; 86(8):823-8. PubMed ID: 3479516
[No Abstract] [Full Text] [Related]
15. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
Chen YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers in the diagnosis of pancreatic carcinoma].
Lemma F; Bombardieri T; Salibra M; Trovato P; De Pasquale MC; Faraone V; Punturiero R; Di Mauro S
Minerva Med; 1989 Jul; 80(7):645-9. PubMed ID: 2779818
[No Abstract] [Full Text] [Related]
17. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
Ohkura H; Sakawaki T
Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
Takahashi H; Miyazaki H; Deura M; Shimizu Y; Asukata I; Kameda H
Gan No Rinsho; 1985 May; 31(6 Suppl):623-30. PubMed ID: 2411964
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]